

## CURRENT TREATMENT OPTIONS IN HAEMATOLOGICAL MALIGNANCIES & SUPPORT THERAPY

**Tuesday 1<sup>st</sup> July 2014**

**28 Portland Place, London W1B 1LY**

**Chairs:** Professor Adrian Newland, *Barts Health NHS Trust*

Dr Emma Morris, *University College London Hospitals NHS Foundation Trust*

11:30	Registration	
12:15	Progress in antibodies in lymphoid malignancies	<b>Dr Stephen Robinson</b> <i>University Hospital Bristol</i>
12:45	Vaccines for acute leukaemia patients	<b>Dr Emma Morris</b> <i>UCLH</i>
13:00	Challenges in the management of AML	<b>Dr Mike Dennis</b> <i>Christie Hospital, Manchester</i>
13:30	Lunch	
14:15	Complications of the post-transplant patients	(TBC)
14:45	What's new in CLL – drugs on the horizon	<b>Dr George Follows</b> <i>Addenbrooke's Hospital, Cambridge</i>
15:15	Non-chemotherapy treatment for lymphoma: how should we use new agents in NHL	<b>Dr Andrew McMillan</b> <i>Nottingham City Hospital</i>
15:45	Coffee	
16:10	Myeloma – rational treatment of relapsed refractory disease	<b>Professor Graham Jackson</b> <i>RVI, Newcastle</i>
16:40	VTE in haemato-oncology patients	<b>Professor Beverley Hunt</b> <i>Guy's and St Thomas' Hospital, London</i>
17:00	Adult ALL – update on new agents	<b>Dr Andrew McMillan</b> <i>Nottingham City Hospital</i>
17:15	Cancer Drugs Fund – update & state of play	<b>Professor Adrian Newland</b> <i>Barts Health NHS Trust</i>
17:30	Close	

*The sponsors have had no input into the agenda, however they have provided a financial contribution to the cost of running this meeting.  
Amgen, Ariad, Celgene, EUSA Pharma, GlaxoSmithKline, Janssen, Napp, Nordmedica, Roche, Sanofi, Takeda, Therakos & LLR*



**Register online at [www.hartleytaylor.co.uk](http://www.hartleytaylor.co.uk) or email [hannah@hartleytaylor.co.uk](mailto:hannah@hartleytaylor.co.uk)**

**Registration Fee £50.00**